Purpose For women with stage IV breast cancer (BC), the association between survival time (ST) and use of aggressive end-of-life (EOL) care is unknown. Methods We used the SEER-Medicare database to identify women with stage IV BC diagnosed 2002-2011 who died by 12/31/2012. Aggressive EOL care was defined as receipt in the last month of life: [1 ED visit, [1 hospitalization, ICU admission, life-extending procedures, hospice admission within 3 days of death, IV chemotherapy within 14 days of death, and/or C10 unique physician encounters in the last 6 months of life. Receipt of aggressive EOL care and hospice in the last month of life were determined using claims, and multivariable analysis was used to identify factors associated with receipt. Costs of care were also evaluated. Results We identified 4521 eligible patients. Of these, 2748 (60.8%) received aggressive EOL care. Factors associated with aggressive EOL care were race (OR 1.45, 95% CI 1.19-1.81 for blacks compared to whites) and more frequent oncology office visits (OR 1.56, 95% CI 1.28-1.90). Patients who lived [12 months after diagnosis were less likely to receive aggressive EOL care (OR 0.44, 95% CI 0.38-0.52), and more likely to utilize hospice (OR 1.43, 95% CI 1.21-1.69) compared to patients who lived B6 months. Patients with a shorter ST had significantly higher costs of care per-month-alive compared to patients with longer ST. Conclusion Patients with a shorter ST were more likely to receive aggressive EOL care and had higher costs of care compared to patients who lived longer.
Introduction
Compared to other types of cancer, patients with metastatic breast cancer (MBC) may utilize more aggressive end-oflife (EOL) care. A population-based study of 215,484 elderly patients who died of cancer between 1993 and 2000 showed that patients with breast cancer compared to patients with lung cancer were 63% more likely to receive chemotherapy within the last 14 days of death, 21% more likely not to utilize hospice care, and 21% more likely to be admitted to hospice within 3 days of death [1] . Similarly, a single-institution evaluation of patients with MBC reported that one-third of women did not utilize hospice services, and of the patients who were admitted to hospice, only 22% had a documented advanced directive discussion in their medical record [2] .
The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) recommend against aggressive care at the EOL [3] [4] [5] . Aggressive EOL care includes in the last month of life: more than one emergency department (ED) visit, more than one hospital admission, admission to the intensive care unit (ICU), receipt of life-extending procedures such as a feeding tube, ventilation, or cardiopulmonary resuscitation (CPR), admission to hospice within 3 days of death, receipt of intravenous (IV) chemotherapy within 14 days of death, and/or C10 unique physician encounters in the last 6 months of life [6] [7] [8] 12] . Despite these recommendations, 30-65% of patients with advanced cancer receive aggressive EOL care [6] [7] [8] [9] [10] . Use of hospice has been shown to reduce the number of ED visits, hospitalizations, and total costs of care, and is associated with improved quality of EOL care [3, [11] [12] [13] . NCCN guidelines call for consideration of hospice care in the management of patients with advanced cancer who experience disease progression or unacceptable toxicity from treatment; despite these recommendations, hospice care is only utilized in about 60% of patients with advanced cancer, and when utilized, 10.9% enroll within three days of death [3, 14, 15] . A populationbased study of 6956 women with ovarian cancer found that, despite a significant increase of hospice use from 1997 to 2007, aggressive EOL care also increased significantly, suggesting that hospice may be introduced too late in the course of disease [8] .
Survival time may also impact the receipt of aggressive EOL care. A population-based analysis showed that at least 65% of patients with poor prognosis cancers, including lung and pancreatic cancers, utilized aggressive EOL care. It is unknown how survival time (ST) impacts receipt of aggressive EOL care among patients with stage IV breast cancer (BC). The objectives of this study were to determine the association between length of time alive with stage IV BC and aggressive EOL care, and its associated costs.
Methods

Data source
We used data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database [16] . The SEER registries encompass approximately 28% of the US population and the database contains information on patient sociodemographic characteristics, tumor details, and survival outcomes for cancers occurring within those populations [17] . Linkage with the Medicare database allows the longitudinal evaluation of cancer care and characterizes inpatient, outpatient, and physician-billed services, including diagnoses, and healthcare costs [18] .
Cohort selection
We identified all women C66 years of age with histologically confirmed stage IV breast cancer diagnosed between January 1, 2002 and December 31, 2011, who died by December 31, 2012. We excluded patients who were enrolled in a Medicare health maintenance organization or who were not continuously enrolled by Medicare Parts A and B for a period of 12 months before diagnosis through death or the end of the study period. We also excluded patients who were enrolled in Medicare due to end-stage renal disease, as well as patients with other primary cancers. We also excluded patients whose reporting source of death was autopsy or death certificate, whose reason for entitlement was not age, whose date of death differed by [3 months between SEER and Medicare, and those with missing claims from 45 days before diagnosis through 180 days after diagnosis. Patients who died within 30 days of diagnosis were also excluded.
End-of-life care
Aggressive EOL care was defined as in the last month of life having any one of the following: more than one ED visit, more than one hospital admission, greater than 14 days hospitalized, admission to the ICU, admission to hospice within 3 days of death, receipt of IV chemotherapy within 14 days of death, or the use of life-extending procedures (feeding tube placement, ventilation, and/or cardiopulmonary resuscitation) [6] [7] [8] 10] . We also included ten or more encounters with unique physicians in the last 6 months of life in our definition of aggressive EOL care [10] . We identified ICU admissions using International Classification of Diseases, Ninth Revision (ICD-9) codes (96.7x) and diagnosis-related group codes (475 or 483) for mechanical ventilation and the ICU indicator variable in the Medicare inpatient file [19, 20] . Hospice admissions were identified through billing claims in the Medicare hospice files and were categorized as home and/or facility hospice (hospital and/or skilled nursing facility [SNF] ). In addition, we examined length of stay (LOS) among patients admitted to the hospital, ICU, and hospice in the last month of life [8] .
Among patients who utilized hospice, the source of referral (inpatient, SNF, or outpatient) was identified using billing claims; patients who enrolled in hospice within 2 days of hospital discharge were characterized as inpatient referrals, patients enrolled within 2 days of SNF discharge were characterized as SNF referrals, and other enrollments were characterized as outpatient referrals [8, 21] .
Survival time (ST)
Patients were categorized by the time from diagnosis of breast cancer until death. This was classified as: B6 months, 6-12 months, and[12 months.
Costs of care
Costs of care were calculated from Medicare reimbursement claims from physician, hospital, outpatient, durable medical equipment, and hospice filings between the date of diagnosis and the date of death [22, 23] . Costs were categorized as costs per-month-alive after diagnosis, which were calculated as totals costs divided by the number of months alive after diagnosis; and costs in the last month of life.
Location of death
Location of death (LOD) was determined using discharge status codes on claims from the death date, including care received in the hospital, SNF, facility and home hospice. Patients without a hospice discharge prior to their death date were considered to have died in hospice. If there was a hospital or SNF claim on their death date their LOD was categorized as facility hospice; if there was no facility claim on their death date their LOC was categorized as home hospice. If patients were never enrolled in hospice or discharged prior to their death date, with hospital or SNF claims on their death date their LOD was considered hospital or SNF, respectively; if no claims on their death date their LOD was considered home without hospice [24] .
Covariates
Demographic covariates included age at diagnosis (66-69, 70-74, 75-79, and C80 years), year of diagnosis, marital status (married, single, unknown), race (white, black, other), hospital location (urban, rural), region (East, Midwest, West), Charlson comorbidity score (0, 1, C2), and socioeconomic status. Tumors were categorized as hormone receptor (estrogen receptor [ER] and/or progesterone receptor [PR]) positive, negative, or unknown. Other covariates included medical oncology office visits, defined as the number of visits per-month alive by tertile (low, medium, high). To define medical oncology office visits, physician files were used to determine provider specialty and date of office visit. Visits were identified through HCPCS codes [23] .
Statistical analysis
Univariate analyses comparing patient and tumor characteristics with patient prognosis were performed with t tests for continuous variables and v 2 tests for categorical variables. We developed logistic regression models to determine the associations between clinical, demographic, and prognostic factors and receipt of aggressive EOL care and hospice care in the last month of life. For analyses of hospice care in the last month of life, hospice enrollment within 3 days of death was excluded from the analysis. Trends over time in median EOL expenditures and expenditure per-month-alive were evaluated by ST. Logistic regression was used to assess the association of year of death with aggressive EOL care utilization and location of death, which was adjusted for patient characteristics described to predict the yearly proportion of patients with each outcome. Then a linear trend test over time using orthogonal polynomial coefficients was conducted to determine if there was significant change in the adjusted proportions between 2002 and 2011 [8, 25] . All analyses were conducted with SAS version 9.4 software (SAS Institute, Cary, NC) and STATA 14 software (College Station, TX). All statistical tests were two-sided, with a \ 0.05.
Results
We identified 4521 women with an initial diagnosis of MBC between 2002 and 2011 who were eligible for analysis. The cohort was predominantly white (83.0%), without comorbidities (48.7%), and had hormone receptor (HR)-positive MBC (56.3%, Table 1 ). The median survival of the total cohort was 9.8 months, while 2040 (45.1%) patients lived at least 12 months from their diagnosis. The majority of patients 2748 (60.8%) received aggressive EOL care as defined (Supplemental Table 1 ). The most common LOD was home hospice (37.7%) followed by the hospital (22.0%).
In a multivariable model ( Among the total cohort, 62.8% of patients enrolled in hospice care at some point during their treatment course. The majority of patients enrolled in hospice had outpatient referrals (55.4%, Total costs per-month-alive and in the last month of life were significantly higher among patients who lived B6 months compared to patients who lived 6-12 months and [12 months (Fig. 1) . The majority (65.5%) of total costs per-month-alive were related to inpatient care, and inpatient care costs were significantly higher among patients who lived B6 months compared to patients who 
Discussion
In our population-based study of women with stage IV breast cancer who expired, we found that approximately 60% of patients diagnosed with BC received aggressive EOL care, and that patients with a shorter survival time were more likely to receive aggressive EOL care and less likely to receive hospice. Patients who live B6 months from their diagnosis have higher EOL costs compared to those who live beyond 6 months, and the bulk of these costs are attributed to inpatient care. Despite an increase in hospice use over time, costs per-month alive have increased among all patients with MBC, and particularly among lose who live B6 months. Hospice care at the end-of-life is considered an essential component of high quality care [7, 24, 26] . In an analysis of cancer patients using Medicare data from 2003 to 2010, approximately one quarter of deaths occurred in the hospital, and over 60% of patients were hospitalized in the last month of life [27] . In 2010, 61.3% of patients enrolled in hospice, and 10.9% enrolled in the last three days of life; the average hospice LOS was only 9 days [27] . Patients with longer admissions to hospice ([3 days) reported higher quality of life, and their caregivers were significantly less likely to experience major depressive disorder after their loved one's death [28] [29] [30] . We found a significant increase in the number of patients with MBC who died in hospice from 2002 to 2011, and a significant decrease in hospital and skilled nursing facility deaths. Despite this trend, the mean hospice LOS was only 10.9 days, suggesting that the majority of patients are still enrolling within two weeks of death.
Patients who lived a short time with MBC (\6 months) were more than twice as likely to utilize aggressive EOL care and one-third less likely to utilize hospice care, compared to patients who lived longer than 6 months from diagnosis. Compared to patients who lived longer, patients who died within 6 months of diagnosis were more likely to die in the hospital or in a skilled nursing facility and less likely to die at home. These results are similar to a population-based analysis of EOL care among elderly patients with poor prognosis cancers which found frequent hospitalizations and ICU admissions in the last month of life, and an average hospice LOS of 8.4 days [10] .
It is possible that patients who die quickly after diagnosis don't establish a relationship with a multidisciplinary care team to discuss advanced care planning and, therefore, they utilize more aggressive EOL care. Interestingly, we found that patients who saw their oncologists more frequently were more likely to utilize aggressive EOL care. In our previous work, we found that patients who had more frequent oncology visits were up to three times more likely to be extremeusers of disease monitoring tests, and that patients who were extreme-users of disease monitoring tests were more likely to utilize aggressive EOL care [23] . These findings suggest that it is possible that patients and/or physicians who are overlyaggressive with breast cancer treatment may drive healthcare utilization apart from disease severity. Previous research has shown significant racial/ethnic disparities related to adequacy of pain and symptom control, and perceived unmet needs for supportive services [31] [32] [33] [34] . In addition, other studies have found that among patients with MBC at the EOL, elderly black women were less likely to utilize hospice [34] . In addition to underuse of services, disparities also exist with overuse of treatment in the EOL setting. Compared to elderly white women, elderly black women with MBC are more likely to die in the hospital, and be admitted to the ICU, hospital, or ED within the last month of life [34] . These results are also similar to our own results which found that elderly black women with MBC were more likely to utilize aggressive EOL care compared to elderly white women with MBC.
Our work has several important limitations. The SEERMedicare database includes only patients who are 65 years or older with Medicare insurance and may not be generalizable to all patient populations. We only included patients who died in our total cohort which may result in selection bias, meaning that patients who survived for a long period of time were excluded from our analysis; however, we expect this effect to be small. We included patients who died of all causes, but the majority, 3375 (74.7%) of patients included died from breast cancer. Additionally, a sensitivity analysis was performed on all analyses among only those patients whose cause of death was attributed to breast cancer, and all results were similar. Our cost estimates did not include costs associated with oral therapies, and, therefore, may be an underestimate of total cancer costs, but are similar to EOL care costs reported in the literature [35, 36] . Survival time was determined retrospectively by the interval from diagnosis until death; there is currently no objective prospective method to determine which patients will live longer and this may present a challenge to apply our results in clinical practice. In summary, we found approximately 60% of elderly women with MBC received aggressive EOL care. Patients who died quickly after diagnosis were more likely to receive aggressive EOL care and have higher EOL care costs compared to patients who lived longer. Patients with rapidly progressive MBC should be targeted for interventions to curb aggressive EOL care and introduce advanced care planning earlier in the treatment course. 
